From Molecule to Market: How Life Sciences Companies are Compressing the Data-to-Decision Curve with Databricks

The life sciences industry sits at an extraordinary inflection point. The same AI capabilities that are reshaping drug discovery are now being applied to clinical trial design, real-world evidence generation, digital twin simulation and commercial launch strategy — and the organizations moving fastest are those who've unified these workloads on a single data intelligence platform. In this session, we take a sweeping look at how Databricks is powering the full life sciences value chain: accelerating target identification and molecular screening in R&D, enabling adaptive trial designs with richer patient data, building synthetic cohorts and digital twins that reduce time and cost, and equipping commercial teams with the AI-driven insights needed to reach the right patients faster. We'll explore the common thread running through each of these use cases — a governed, interoperable data foundation — and make the case that the most durable competitive advantage in life sciences today is not any single model or dataset, but the platform on which all of them live.